Unity Biotechnology (NASDAQ:UBX) Announces Earnings Results

by · The Cerbat Gem

Unity Biotechnology (NASDAQ:UBX – Get Free Report) announced its earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02, Zacks reports.

Unity Biotechnology Price Performance

Shares of NASDAQ:UBX traded up $0.02 during mid-day trading on Thursday, reaching $1.17. 5,007 shares of the company traded hands, compared to its average volume of 63,100. The company’s 50 day moving average price is $1.43 and its 200-day moving average price is $1.47. The firm has a market cap of $19.71 million, a PE ratio of -0.88 and a beta of 0.83. Unity Biotechnology has a 52 week low of $1.11 and a 52 week high of $2.26.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Unity Biotechnology in a report on Thursday, August 22nd. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Unity Biotechnology in a research note on Thursday, August 8th.

Get Our Latest Analysis on UBX

Unity Biotechnology Company Profile

(Get Free Report)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

Read More